AI build stays in front
Equity leadership didn’t change lanes. The AI buildout remained the market’s favorite trade, and the leadership broadened the way it usually does late in a run: away from the glamorous chips and into the plumbing that keeps data centers alive.
Vertiv (VRT) is still the clean read-through—up ~80% over the past year—because power and cooling are hard constraints when demand for compute keeps rising. The fact that VRT and Comfort Systems USA showed up among top Q1 movers is the tell: the AI basket is widening into electrical, HVAC, and services. The market bought throughput, not vibes.
Semis stayed constructive on the same playbook: stick with the leaders, take the upgrades, and don’t fight the tape.
- Micron (MU) rose on analyst upgrades. The bull case is still memory pricing plus HBM leverage as training and inference workloads scale.
- Broadcom (AVGO) moved higher with the AI narrative intact, even with margin concerns still in the background. Investors are balancing near-term profitability against custom silicon/networking exposure and whether hyperscaler capex holds up.
- NVIDIA (NVDA) added again. When risk appetite is on, it’s the default long and everyone knows it.
- AMD (AMD) was flat-to-up on bullish commentary. The optimism is there, but it’s more conditional—competitive accelerators, fuller stack, and execution.
On the platform side, it was mostly price-target math. Alphabet (GOOGL) caught a bid after Wells Fargo raised its price target to $397. Meta (META) was flat/down after Morgan Stanley trimmed its price target to $775. That split is basically the market keeping one eye on AI spend and another on multiples.
Catalysts on deck
Two event-driven stories put dates and product cycles back in focus.
First, reports that SpaceX (unlisted) has filed confidential IPO paperwork, with timing floated as soon as June, created a real catalyst window for the space/aerospace theme. Even without a ticker, a credible timeline pulls positioning forward: peers and adjacent names tend to get bought sooner, the story horizon compresses from “sometime this year” to “watch the calendar,” and volatility shows up right when the narrative gets tradable.
Second, healthcare got another GLP-1 escalation. Eli Lilly launched Foundayo, a daily oral GLP-1 weight-loss pill, positioned against the possibility of a future Wegovy pill. Oral delivery shifts the fight toward convenience and access, which can expand the category while tightening the race on efficacy, tolerability, pricing, and manufacturing scale. The market is moving past the idea that injections are “good enough” forever.
Yield stayed steady
Away from momentum, the carry sleeve did what it’s supposed to do. A cluster of income and fixed-income ETFs declared monthly distributions and traded largely flat, consistent with a session that didn’t force a big rates or credit rethink.
Declared distributions:
- XLB: $0.3196 (flat)
- SCHI: $0.0931 (flat)
- SPYD: $0.3164 (flat)
- SCHJ: $0.0901 (flat)
- SPSB: $0.0673 (flat)
- HYIB: $0.1642 (flat)
The set spans short/intermediate corporates (SCHJ, SCHI), ABS (SPSB), defined-maturity high yield (HYIB), and equity premium income (SPYD). Broad exposure, no obvious panic bid.
Macro didn’t disturb the frame. ADP March private-sector hiring came in at +62,000 (reported above expectations), led by healthcare and construction. It’s not NFP, but it supports the “still growing, uneven by sector” setup—healthcare looks structural, and construction holding up matters when rates are supposed to be the villain.
Internationally, Nigerian banks raised $3.4B (4.7T naira) to meet new capital requirements, and the Central Bank of Nigeria confirmed recapitalization compliance. Not a front-page trading catalyst, but a clean stability marker in a market that rarely gets clean ones.
AI was the bid, catalysts pulled timelines forward, and everything else mostly behaved.